Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Recro Pharma Inc    REPH

RECRO PHARMA INC

(REPH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Recro Pharma : in New Supply Agreement with Novartis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 08:58am EDT

By Michael Dabaie

Recro Pharma said Monday it entered into a five-year manufacturing and supply agreement with Novartis.

Under the agreement, the company's Recro Gainesville division will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules through 2023, the company said.

The prior Novartis supply contracts were set to expire in late 2019 and mid-2020, respectively, and provided for two revenue components, product manufacturing revenue and royalty revenue. These agreements were consolidated into the new agreement, which provides for product manufacturing revenue that is expected to provide similar total-revenue-per-capsule economics as the two prior revenue components combined.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -2.17% 77.03 Delayed Quote.3.69%
RECRO PHARMA INC 1.58% 8.36 Delayed Quote.17.75%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RECRO PHARMA INC
04/18RECRO PHARMA, INC. : Entry into a Material Definitive Agreement, Financial State..
AQ
04/17RECRO PHARMA : Announces Six-Year Extension of License and Supply Agreement Betw..
AQ
04/16RECRO PHARMA : Announces Six-Year Extension of License and Supply Agreement Betw..
AQ
04/11Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at ..
GL
04/05RECRO PHARMA, INC. : Costs Associated with Exit or Disposal Activities, Other Ev..
AQ
04/03RECRO PHARMA : Restructures Acute Care Segment While Continuing To Execute on St..
AQ
03/28RECRO PHARMA, INC. : Entry into a Material Definitive Agreement, Change in Direc..
AQ
03/26RECRO PHARMA : Appoints Arnaud Ajdler to Its Board of Directors
AQ
03/25RECRO PHARMA : Receives Complete Response Letter from the FDA for Intravenous Me..
AQ
03/25RECRO PHARMA : Receives Complete Response Letter from the FDA for Intravenous Me..
AQ
More news
Financials ($)
Sales 2019 84,8 M
EBIT 2019 -30,8 M
Net income 2019 -37,9 M
Debt 2019 53,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 2,79x
EV / Sales 2020 2,20x
Capitalization 184 M
Chart RECRO PHARMA INC
Duration : Period :
Recro Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECRO PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 11,2 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Gerri A. Henwood President, Chief Executive Officer & Director
Wayne B. Weisman Chairman
Michael Celano Secretary & Chief Operating Officer
Ryan D. Lake Chief Financial Officer
Stewart Mccallum Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RECRO PHARMA INC17.75%184
GILEAD SCIENCES0.64%80 255
VERTEX PHARMACEUTICALS1.48%42 991
REGENERON PHARMACEUTICALS-10.75%35 789
GENMAB5.11%10 423
SAREPTA THERAPEUTICS INC6.88%8 594